Co-stimulatory Receptors

Cat. No.

A54018

CAS No.

2878367-20-3

Vedastotug

Vedastotug is a human monoclonal antibody that specifically targets TNFRSF4, also known as OX40 or CD134. This antibody plays a critical role in modulating T cell activation and proliferation, making it a valuable tool for immunological research and therapeutic studies. Its applications include investigating immune responses in cancer and autoimmune diseases, as well as evaluating potential treatments that enhance T cell function. The corresponding isotype control is Human IgG1 kappa, Isotype Control.

Cat. No.

AT0034

Anti-TNFRSF5/CD40 Antibody

Cat. No.

AT0079

CAS No.

3014361-59-9

Ciltistotug

Ciltistotug is a monoclonal antibody that specifically targets CD40 (TNFRSF5) on human cells. Upon binding to CD40, Ciltistotug activates immune cells, thereby exerting both immunostimulatory and antitumor effects. This antibody is particularly valuable in the study of cancer immunotherapy, offering potential insights into the modulation of immune responses against tumors.

Cat. No.

AT0138

CAS No.

880486-59-9

Dacetuzumab

Dacetuzumab (SGN-40) is a humanized IgG1 monoclonal antibody targeting CD40, demonstrating potent anti-lymphoma properties. This therapeutic antibody exerts its effects through immune effector functions, including antibody-dependent cellular cytotoxicity and phagocytosis (ADCC/ADCP), leading to the effective elimination of tumor cells. Dacetuzumab is primarily utilized in research focused on multiple myeloma, offering significant insights into disease mechanisms and potential therapeutic strategies.

Cat. No.

AT0141

CAS No.

2055640-86-1

Mitazalimab

Synonyms: ADC-1013; JNJ-64457107

Mitazalimab (ADC-1013; JNJ-64457107) functions as an FcγR-dependent CD40 agonist, specifically designed to exhibit tumor-directed activity. This therapeutic agent effectively activates antigen-presenting cells, such as dendritic cells (DCs), thereby initiating the activation of tumor-reactive T cells. Consequently, Mitazalimab promotes the infiltration and activation of tumor-specific T cells, which are instrumental in targeting and destroying tumor cells. Additionally, this compound plays a crucial role in remodeling the tumor-infiltrating myeloid microenvironment, enhancing its therapeutic efficacy against cancerous tissues.

Cat. No.

AT0266

ADG-106

ADG-106 is a fully human agonistic monoclonal IgG4 antibody targeting CD137 (4-1BB). This antibody is designed to activate CD137 through potent FcγRIIB-mediated crosslinking, concurrently antagonizing CD137 ligands. For isotype control purposes, Human IgG4 (S228P) kappa, Isotype Control is recommended. This product is pivotal in studies focused on the modulation of immune responses, particularly in the context of immunotherapy and cancer research.

Cat. No.

AT0328

CAS No.

1622140-49-1

Selicrelumab

Selicrelumab is an agonistic antibody targeting CD40, known to modulate the tumor microenvironment significantly. This antibody is specifically designed for use in research focused on pancreatic cancer and neoadjuvant therapies. Selicrelumab facilitates the study of CD40's role in oncologic pathways and immune responses, making it a valuable tool for advancing cancer treatment modalities.

Cat. No.

AT0329

CAS No.

2444297-08-7

Boserolimab

Synonyms: MK-5890

Boserolimab (MK-5890) is a humanized agonist monoclonal antibody designed to target CD27. By binding to CD27, it delivers a costimulatory signal that significantly enhances T-cell-mediated immune responses. This antibody is pivotal for research focused on immunotherapy and the modulation of immune responses in various diseases.

Cat. No.

AT0339

CAS No.

2642171-64-8

Exlinkibart

Synonyms: LVGN-6051

Exlinkibart (LVGN-6051) is a humanized IgG1κ monoclonal antibody that specifically targets TNFRSF9. This antibody has been engineered using advanced complementarity-determining region (CDR) grafting technology to enhance its specificity and binding affinity. Exlinkibart is designed for use in research studies aimed at elucidating the biological roles of TNFRSF9 and may be applicable in therapeutic development studies focusing on diseases mediated by this receptor.

Cat. No.

AT0352

CAS No.

2031153-61-2

Iscalimab

Synonyms: CFZ-533; OM11-62MF

Iscalimab (CFZ-533) is a non-depleting IgG1 monoclonal antibody that selectively targets CD40 with a dissociation constant (K_D) of 0.3 nM. This high-affinity interaction underscores its utility in the study of immunological disorders, including Graves' hyperthyroidism and various autoimmune diseases. Iscalimab is engineered to modulate the CD40-CD40L pathway, pivotal in immune regulation, without causing depletion of immune cells, making it an ideal tool for advanced immunological research and therapeutic investigations.

Cat. No.

AT0451

CAS No.

2377152-49-1

CTX-471

CTX-471 is a fully human monoclonal antibody targeting CD137, a receptor involved in the regulation of immune responses. This antibody demonstrates high binding affinity to recombinant CD137 from various species, with dissociation constants (Kd) of 50 nM for human, 61 nM for cynomolgus macaque, and 748 nM for mouse CD137. CTX-471 is primarily utilized in research focused on immunomodulation and oncology, offering a valuable tool for studies aimed at understanding and manipulating immune pathways in cancer therapy.

Cat. No.

AT0497

FR104

FR104 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CD28. This antibody consists of a human IgG2 heavy chain and a human kappa light chain, with an estimated molecular weight of 145 kDa. For experimental control purposes, Human IgG2 kappa, Isotype Control is recommended.

Cat. No.

AT0530

BMS-986178

BMS-986178 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target TNFRSF4, also known as OX40 or CD134. This antibody comprises a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Cat. No.

AT0544

CAS No.

2642171-59-1

Dalnicastobart

Synonyms: LVGN-7409

Dalnicastobart (LVGN-7409) is a human IgG1κ monoclonal antibody specifically designed to target CD40, also known as TNFRSF5. This antibody is engineered to bind selectively to CD40, a member of the tumor necrosis factor receptor superfamily, playing a crucial role in immune system regulation and the promotion of immune responses. Dalnicastobart is utilized predominantly in research focused on immunological responses and potential therapeutic interventions for autoimmune diseases and cancers.

Cat. No.

AT0549

CAS No.

2489390-15-8

KY-1044

Synonyms: Alomfilimab; SAR 445256

KY-1044 (Alomfilimab; SAR 445256) is a fully humanized IgG1 monoclonal antibody that selectively targets the inducible costimulatory receptor (ICOS). This antibody is designed to deplete ICOS-high expressing cells through the mechanism of antibody-dependent cellular cytotoxicity (ADCC), facilitated by the engagement of FcγRIIIa receptors. Additionally, KY-1044 serves as a costimulatory molecule for cells expressing lower levels of ICOS, such as CD8+ effector T cells, via FcγR-dependent clustering. This dual functionality allows KY-1044 to modulate the differential expression of ICOS across various T-cell subtypes, thereby enhancing the intratumoral immune contexture and promoting an effective antitumor immune response. KY-1044 is primarily researched for its potential therapeutic applications in oncology, focusing on its ability to manipulate immune responses within the tumor microenvironment.

Cat. No.

AT0610

CAS No.

1629760-27-5

Cifurtilimab

Synonyms: SEA-CD40

Cifurtilimab (SEA-CD40) is an agonistic, non-fucosylated human IgG1 monoclonal antibody that targets CD40, a co-stimulatory protein found on antigen-presenting cells. This antibody has been engineered to enhance immune activation and exhibits significant antitumor activities, making it a valuable tool for research in cancer immunotherapy.

Cat. No.

AT0620

CAS No.

2765071-95-0

Abiprubart

Abiprubart is a human IgG4 κ monoclonal antibody targeting CD40. For accurate experimental controls, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.

Cat. No.

AT0633

CAS No.

2230138-89-1

Revdofilimab

Synonyms: ABBV-368

Revdofilimab (ABBV-368) is a human IgG1 monoclonal antibody designed as an agonist targeting OX40, a constituent of the TNF receptor superfamily. OX40 is predominantly expressed on subsets of activated and memory T cells as well as T regulatory cells. This antibody facilitates the modulation of immune responses, making it a valuable tool in immunological research and therapeutic development.

Cat. No.

AT0659

CAS No.

2226292-20-0

Giloralimab

Synonyms: ABBV-927

Giloralimab (ABBV-927) is a potent agonistic monoclonal antibody targeting CD40. This antibody is designed to modulate immune responses, making it a valuable tool for cancer research. Its agonistic properties can potentially enhance anti-tumor immunity, providing a promising approach for investigational studies in oncology.

Cat. No.

AT0700

CAS No.

2916519-49-6

Nuvustotug

Nuvustotug is a human monoclonal antibody of the IgG1κ subtype that specifically targets TNFRSF4. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Cat. No.

AT0701

Anti-CD28 Antibody (9.3)

The Anti-CD28 Antibody (9.3) is a chimeric mouse IgG2a antibody designed to specifically target human CD28. This antibody serves as a crucial tool for the modulation and study of CD28 signaling pathways, which are vital in T-cell activation and immune response. For accurate experimental control, it is recommended to use Mouse IgG2a kappa as an isotype control. This antibody is suitable for a variety of immunological applications, including flow cytometry, immunoprecipitation, and other assays requiring precise CD28 targeting.

Cat. No.

AT0768

Anti-CD40 Antibody (G28.5)

The Anti-CD40 Antibody (G28.5) is a chimeric mouse monoclonal antibody of the IgG1 kappa isotype, specifically designed to target human CD40. For accurate experimental control, it is recommended to use Mouse IgG1 kappa Isotype Control. This antibody is suitable for a range of immunological assays investigating the role of CD40 in immune responses and its implications in immunological research and therapeutic development.

Cat. No.

AT0781

CAS No.

2253891-70-0

Tecaginlimab

Synonyms: BNT-312; DuoBody-CD40x-4-1BB; GEN1042

Tecaginlimab (BNT-312) is an Fc-inert bispecific antibody engineered for the dual targeting and conditional stimulation of CD40 and 4-1BB receptors. This antibody is designed to enhance the priming and reactivation of tumor-specific immune responses, making it a valuable tool for research in cancer immunotherapy. Tecaginlimab's unique ability to engage both CD40 and 4-1BB under specific conditions allows for precise modulation of immune activation, potentially leading to improved therapeutic outcomes in oncology research.

Cat. No.

AT0825

MK-4166

MK-4166 is a humanized IgG1 monoclonal antibody designed as an agonist targeting the glucocorticoid-induced TNFR-related protein (GITR). This antibody facilitates the enhancement of proliferation in both naïve and tumor-infiltrating T lymphocytes, making it a critical tool in the study of T cell dynamics and cancer immunotherapy. MK-4166's specificity for GITR and its agonistic properties position it as a valuable agent for research focused on immune response modulation within oncological environments.

Cat. No.

AT0838

CAS No.

2329669-80-7

Izuralimab

Izuralimab is a bispecific IgG1 monoclonal antibody designed for simultaneous targeting of the inducible T-cell costimulator (ICOS/CD278) and the programmed death-1 receptor (PD-1). This dual specificity facilitates a coordinated modulation of T-cell responses, enhancing immune activation against tumors while potentially mitigating autoimmune responses. Izuralimab is utilized predominantly in oncological research to investigate therapeutic strategies for enhancing antitumor immunity.